1. Yao T, Utsunomiya T, Oya M, Nishiyama K, Tsuneyoshi M. Extremely well-differentiated adenocarcinoma of the stomach: clinicopathological and immunohistochemical features. World J Gastroenterol. 2006; 12:2510–6.
Article
2. Joo M, Han SH. Gastric-type extremely well-differentiated adenocarcinoma of the stomach: a challenge for preoperative diagnosis. J Pathol Transl Med. 2016; 50:71–4.
Article
3. Kim KM, Bilous M, Chu KM, et al. Human epidermal growth factor receptor 2 testing in gastric cancer: recommendations of an Asia-Pacific task force. Asia Pac J Clin Oncol. 2014; 10:297–307.
Article
4. Jeong JH, Kim J, Hong YS, et al.
HER2 amplification and cetuximab efficacy in patients with metastatic colorectal cancer harboring wild-type RAS and BRAF. Clin Colorectal Cancer. 2017; 16:e147–52.
5. Hong YS, Kim J, Pectasides E, et al. Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models. PLoS One. 2014; 9:e109440.
6. Waters KM, Salimian KJ, Voltaggio L, Montgomery EA. Refined criteria for separating low-grade dysplasia and nondysplastic Barrett esophagus reduce equivocal diagnoses and improve prediction of patient outcome: a 10-year review. Am J Surg Pathol. 2018; 42:1723–9.
7. WHO Classification of Tumours Editorial Board. WHO classification of tumours of the digestive system tumours. Lyon: IARC Press;2019.
8. Humphris JL, Jones DB. Subepithelial mass lesions in the upper gastrointestinal tract. J Gastroenterol Hepatol. 2008; 23:556–66.
Article
9. Niimi C, Goto H, Ohmiya N, et al. Usefulness of p53 and Ki-67 immunohistochemical analysis for preoperative diagnosis of extremely well-differentiated gastric adenocarcinoma. Am J Clin Pathol. 2002; 118:683–92.
Article
10. Nakayama T, Ling ZQ, Mukaisho K, Hattori T, Sugihara H. Lineage analysis of early and advanced tubular adenocarcinomas of the stomach: continuous or discontinuous? BMC Cancer. 2010; 10:311.
Article